CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout  

RadicavaPositive
AI Analysis

Summary

Shionogi announced a $2 billion acquisition of IntraBio to expand its rare disease portfolio, following its recent acquisition of the ALS drug Radicava.

Importance:7/10
Sentiment:
0.60
M&Arare diseaseacquisitionportfolio expansion
Related Companies

Read the original article

Published by Pharmaceutical Technology on October 6, 2026 10:59 AM

Read Original